Drug resistance surveillance of little value for ART sequencing
- PDF / 142,695 Bytes
- 1 Pages / 623.591 x 841.847 pts Page_size
- 25 Downloads / 172 Views
Discounted life expectancy (years)
Costeffectiveness ($US/lifeyear gained)
2.78 6.71
dominateda
7.30
910
this strategy has a higher cost-effectiveness ratio ($US987/life-year gained) than the next more effective alternative
a
In contrast, starting with an NNRTI regimen followed by PI-based therapy resulted in a greater increase in life expectancy at a similar cost. The resulting costeffectiveness ratios for NNRTI initiation and PI initiation indicate that the boosted PI-regimen was dominated. Sensitivity analyses revealed that, in the base-case scenario, initiating treatment with a PI-based regimen would only become preferable if the prevalence of resistance was > 76%. * Costs (2005 $US) included inpatient length of stay, laboratory tests, clinical procedures, drugs dispensed and outpatient visits. Walensky RP, et al. HIV drug resistance surveillance for prioritizing treatment in 801076999 resource-limited settings. AIDS 21: 973-982, No. 8, 11 May 2007
1173-5503/10/0532-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved
PharmacoEconomics & Outcomes News 14 Jul 2007 No. 532
1
Data Loading...
